These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccine against infectious bovine keratoconjunctivitis: a new approach to optimize the production of highly piliated Moraxella bovis cells. Prieto CI; Bosch A; Zielinski G; Cúneo J; Yantorno OM Vaccine; 2008 Dec; 26(51):6542-9. PubMed ID: 18852003 [TBL] [Abstract][Full Text] [Related]
3. Serologic cross-reactivity of Australian Moraxella bovis to vaccinal bacterin strains as determined by competitive ELISA. McConnel CS; Shum L; Gleeson BL; House JK Aust Vet J; 2008 Apr; 86(4):124-9. PubMed ID: 18363984 [TBL] [Abstract][Full Text] [Related]
4. Characterisation and quantitation of pilus antigens of Moraxella bovis by ELISA. Lepper AW; Hermans LR Aust Vet J; 1986 Dec; 63(12):401-5. PubMed ID: 2879528 [TBL] [Abstract][Full Text] [Related]
5. The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK). Lepper AW; Atwell JL; Lehrbach PR; Schwartzkoff CL; Egerton JR; Tennent JM Vet Microbiol; 1995 Jul; 45(2-3):129-38. PubMed ID: 7571364 [TBL] [Abstract][Full Text] [Related]
6. The protective efficacy of pili from different strains of Moraxella bovis within the same serogroup against infectious bovine keratoconjunctivitis. Lepper AW; Moore LJ; Atwell JL; Tennent JM Vet Microbiol; 1992 Sep; 32(2):177-87. PubMed ID: 1359693 [TBL] [Abstract][Full Text] [Related]
7. Pathogenicity and immunogenicity of piliated and nonpiliated phases of Moraxella bovis in calves. Jayappa HG; Lehr C Am J Vet Res; 1986 Oct; 47(10):2217-21. PubMed ID: 2877604 [TBL] [Abstract][Full Text] [Related]
8. A Moraxella bovis pili vaccine produced by recombinant DNA technology for the prevention of infectious bovine keratoconjunctivitis. Lepper AW; Elleman TC; Hoyne PA; Lehrbach PR; Atwell JL; Schwartzkoff CL; Egerton JR; Tennent JM Vet Microbiol; 1993 Jul; 36(1-2):175-83. PubMed ID: 7901935 [TBL] [Abstract][Full Text] [Related]
9. Randomized controlled field trial to assess efficacy of a Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis. Angelos JA; Gohary KG; Ball LM; Hess JF Am J Vet Res; 2012 Oct; 73(10):1670-5. PubMed ID: 23013196 [TBL] [Abstract][Full Text] [Related]
10. Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis pilin-Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. Angelos JA; Bonifacio RG; Ball LM; Hess JF Vet Microbiol; 2007 Dec; 125(3-4):274-83. PubMed ID: 17656049 [TBL] [Abstract][Full Text] [Related]
11. Vaccination against infectious bovine keratoconjunctivitis: protective efficacy and antibody response induced by pili of homologous and heterologous strains of Moraxella bovis. Lepper AW Aust Vet J; 1988 Oct; 65(10):310-6. PubMed ID: 2904257 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of anti-Moraxella bovis pili immunoglobulin-A in tears following intranasal vaccination of cattle. Zbrun MV; Zielinski GC; Piscitelli HC; Descarga C; Urbani LA; Defain Tesoriero MV; Hermida L Res Vet Sci; 2012 Aug; 93(1):183-9. PubMed ID: 21664636 [TBL] [Abstract][Full Text] [Related]
13. Antigenic characterization of Moraxella bovis, Moraxella bovoculi and Moraxella ovis strains with potential use in vaccines. Kowalski AP; Maboni G; Gressler LT; Espíndola JP; Balzan C; Tasca C; Guizzo JA; Conceição FR; Frandoloso R; de Vargas AC Vet Microbiol; 2017 Oct; 210():56-63. PubMed ID: 29103697 [TBL] [Abstract][Full Text] [Related]
15. Antigenic analysis of fimbrial proteins from Moraxella bovis. Moore LJ; Rutter JM J Clin Microbiol; 1987 Nov; 25(11):2063-70. PubMed ID: 2891723 [TBL] [Abstract][Full Text] [Related]
16. Infectivity and virulence of Australian strains of Moraxella bovis for the murine and bovine eye in relation to pilus serogroup sub-unit size and degree of piliation. Lepper AW; Power BE Aust Vet J; 1988 Oct; 65(10):305-9. PubMed ID: 2904256 [TBL] [Abstract][Full Text] [Related]
17. Serologic and protective characterization of Moraxella bovis pili. Lehr C; Jayappa HG; Goodnow RA Cornell Vet; 1985 Oct; 75(4):484-92. PubMed ID: 2865080 [TBL] [Abstract][Full Text] [Related]
18. Detection of shared magnetic antigenic determinants on whole Moraxella bovis pili by use of antisera to cyanogen bromide-cleaved M. bovis pilus protein. Greene WH; Grubbs ST; Potgieter LN Am J Vet Res; 2001 Aug; 62(8):1279-84. PubMed ID: 11497451 [TBL] [Abstract][Full Text] [Related]
19. Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. Angelos JA; Hess JF; George LW Vaccine; 2004 Dec; 23(4):537-45. PubMed ID: 15530703 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of biofilm-forming capacity of Moraxella bovis, the primary causative agent of infectious bovine keratoconjunctivitis. Prieto C; Serra DO; Martina P; Jacobs M; Bosch A; Yantorno OM Vet Microbiol; 2013 Oct; 166(3-4):504-15. PubMed ID: 23907059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]